Abstract:Oncolytic viruses, defined as viruses capable of lysing cancer cells, emerged as a groundbreaking class of therapeutic entities poised to revolutionize cancer treatment. Their mode of action encompasses both direct tumor cell lysis and the indirect enhancement of anti-tumor immune responses. Notably, four leading contenders in this domain, Rigvir® in Latvia, T-VEC in the United States, H101 in China and Teserpaturev (DELYTACT®) in Japan, have earned approval for treating metastatic melanoma (Rigvir and T-VEC), nasopharyngeal carcinoma and malignant glioma, respectively. Despite these notable advancements, the integration of oncolytic viruses into cancer therapy encounters several challenges. Foremost among these hurdles is the considerable variability observed in clinical responses to oncolytic virus interventions. Moreover, the adaptive immune system may inadvertently target the oncolytic viruses themselves, diverting immune resources away from tumor antigens and undermining therapeutic efficacy. Another significant limitation arises from the presence of preexisting immunity against oncolytic viruses in certain patient populations, hampering treatment outcomes. To circumvent this obstacle, researchers are investigating the utilization of animal viruses, for which humans lack preexisting immunity, as a compelling alternative to human-derived counterparts. In our comprehensive review, we delve into the intricate nuances of oncolytic virotherapy, elucidating the multifaceted mechanisms through which these viruses exert their anti-cancer effects. Furthermore, we provide a thorough examination of animal-derived oncolytic viruses, highlighting their respective strengths and limitations. Lastly, we explore the promising potential of leveraging animal viruses as potent oncolytic agents, offering new avenues for enhancing the efficacy and reach of human cancer therapeutics.

Integrating oncolytic viruses in combination cancer immunotherapy

Oncolytic Viruses in Cancer Immunotherapy

The combination therapy of oncolytic virotherapy

Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic

Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment

Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments

Oncolytic viruses: a new class of immunotherapy drugs

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy

Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors

The emerging field of oncolytic virus-based cancer immunotherapy

From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review

Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy

Current Landscape and Perspective of Oncolytic Viruses and Their Combination Therapies.

Virus-Based Immuno-Oncology Models

Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways

Breaking Barriers: Animal viruses as oncolytic and immunotherapeutic agents for human cancers

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

Oncolytic virotherapy in cancer treatment: challenges and optimization prospects

Enhancing Cancer Immunotherapy: A Novel Approach through the Integration of Oncolytic Virotherapy with CAR-T and NK Cell Therapies

Design and application of oncolytic viruses for cancer immunotherapy

Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?